Social Anxiety Disorder

Neurology·MeSH: Phobia, Social

Prevalence

6090.6 / 100K

Incidence

716.2 / 100K/yr

10 drugs in development·8 companies·11 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
paroxetine	Mylan II B.V. (MYL)
paroxetine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Phase 3(5)

Drug	Company
bnc210	Neuphoria Therapeutics Inc. (NEUP)
fasedienol	Vistagen Therapeutics, Inc. (VTGN)
fasedienol nasal spray - fasedienol	Vistagen Therapeutics, Inc. (VTGN)
ph94b	Vistagen Therapeutics, Inc. (VTGN)
vqw-765	Vanda Pharmaceuticals Inc. (VNDA)

Phase 2(3)

BioSniper tracks 10 drugs in development for Social Anxiety Disorder across 8 companies.

There are 11 clinical trials targeting Social Anxiety Disorder tracked by BioSniper.

The estimated prevalence of Social Anxiety Disorder is approximately 6090.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.